After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication.
See NICE’s guideline on non-Hodgkin’s lymphoma.
After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication.
See NICE’s guideline on non-Hodgkin’s lymphoma.